System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish 1 citation

PubMed: 40849221 DOI: 10.1016/j.breast.2025.104558

Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.

Breast 84:104558

Authors: Leonor Matos, Mette van Ramshorst, Volkmar Müller, Elisa Agostinetto, Sabine Linn, Matteo Lambertini, Veronique Dieras, Fanny le Du, Sofia Braga, Carmen Criscitiello, Katarzyna J Jerzak, Gil Morgan, Sara Brucker, Patricia von Kroge, Renate Haidinger, Gema Rodríguez Recio, Eva Schumacher-Wulf, Mario Fontes Sousa, Francesco Schettini, Elena Laakmann

Affiliations

  • Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • University Medical Center Hamburg-Eppendorf, Germany.
  • Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Service de Oncologie, Rue Meylemeersch 90, 1070, Bruxelles, Belgium.
  • University of Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Department of Medical Oncology at Centre Eugene Marquis, Rennes, France.
  • Institut José de Mello Saúde, Lisbon, Portugal.
  • European Institute of Oncology, Milan, Italy.
  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada.
  • Skåne University Hospital, Lund, Sweden.
  • Department for Women's Health, University Medical Center, Tübingen, Germany.
  • Brustkrebs Deutschland e.V. Hohenbrunn, Germany.
  • Asociación Española Cancer de Mama Metastásico, Madrid, Spain.
  • Mamma Mia! Magazine, Cologne, Germany.
  • CUF - Hospitais e Clínicas, Lisbon, Portugal; Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal.
  • Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • University Medical Center Hamburg-Eppendorf, Germany.

Abstract

BACKGROUND

Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS.

METHODS

International cross-sectional online survey for patients and physicians, distributed from May 2023 to February 2024. Patients with BC diagnosis were deemed eligible for patients' survey completion and BC-treating physicians were invited to fill the physicians' questionnaire.

RESULTS

A total of 529 physicians from 50 countries (80 % European) responded, mostly medical oncologists (70 %) working in academic hospitals (53 %). Most physicians request BIS (65 %), mainly when extracranial progression occurs, especially for HER2+ and triple negative BC (TNBC). Among physicians never performing BIS (35 %), 91 % would in case of proved clinical benefit. A total of 545 patients from 14 European countries completed the questionnaire. Median age was 50 years, 86 % had metastatic BC, 51 % hormone receptor-positive (HR+)/HER2-negative, 30 % HER2-positive (HER2+) and 19 % TNBC. BM were diagnosed in 11.5 % patients with metastatic BC. 85 % patients would like to undergo BIS, especially younger ones (p = 0.02) and with HR-disease (p = 0.03), despite the uncertain clinical benefit. Notably, 91 % of patients would like to receive information regarding BM, while only 13 % of physicians routinely address the issue.

CONCLUSIONS

These results underline the willingness of patients to know more about the prospects of BM development, in contrast to the lack of routine discussion of this topic by physicians. Further investigation is warranted to demonstrate the clinical utility of routine BIS.

MeSH

Breast Neoplasms, Brain, Neoplasms, Breast, Physicians, Breast Diseases